Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina.

Edgar Carnero ContenttiPablo A LópezAgustín PappollaRicardo AlonsoBerenice SilvaNorma DeriMaría E BalbuenaMarcos BurgosGeraldine LueticAmelia Alvez PinheiroMariela CabreraJavier HrybPedro NofalClaudia PestchankerCarlos VrechDarío TavoliniVerónica TkachukGisela ZangaMariano MarrodanMaría Célica YsrraelitJorge CorrealeAdriana CarráBelén FedericoOrlando GarceaNora Fernandez LiguoriLiliana PatruccoEdgardo CristianoDiego GiuntaMarina Alonso SerenaJuan I Rojasnull null

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)

We found an incidence density of breakthrough COVID-19 infection of 3.5 × 10.000 patients/day (95% CI 2.3-6.7) after vaccination in Argentina.

Keyphrases

sars cov
end stage renal disease
risk factors
ejection fraction
newly diagnosed
chronic kidney disease
respiratory syndrome coronavirus
prognostic factors
peritoneal dialysis